Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to assess the ability of Normothermic Machine Perfusion (NMP) to resuscitate moderately steatotic livers for transplantation in patients. This will be a single-site clinical trial placing donor livers with 30-60% macrosteatosis on NMP, and then transplanting those that meet commonly accepted viability criteria. The results of this study could lead to a trial extending NMP transplantation to severely steatotic livers, further expanding the donor organ pool.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Liver Transplantation with Steatotic Liver | Experimental | Graft will be selected if 30-60% macrosteatosis and transplanted into liver transplant recipient with MELD of 15-25. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Normothermic machine perfusion (NMP) of steatotic liver | Device | Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation |
| Measure | Description | Time Frame |
|---|---|---|
| Early allograft dysfunction | Number of participants with initial poor function of liver allograft: measured by presence of 1 or more of the following: aspartate aminotransferase (AST) level higher than 2000 IU/L (to convert to microkatals per liter, multiply by 0.0167) within the first 7 postoperative days; bilirubin 10 mg/dL or higher (to convert to micromoles per liter, multiply by 17.104) on postoperative day 7; international normalized ratio (INR) of 1.6 or higher on postoperative day 7; or graft primary nonfunction within the first 7 days, defined as irreversible graft dysfunction leading to recipient death or emergency retransplant, in the absence of immunologic or surgical causes | First week after transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Intraoperative inotropic support | Number of participants in need of inotropic support to maintain hemodynamics intraoperatively after reperfusion of liver allograft | At reperfusion, 15 minutes, 1 hour, 2 hours, and 3 hours after reperfusion |
| Need for post-operative inotropic support |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Heidi Yeh, MD | Contact | 617-643-4533 | hyeh@mgh.harvard.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Brigham | Recruiting | Boston | Massachusetts | 02114 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of participants in need of inotropic support upon admission to the ICU |
| First 30 days post-transplantation |
| Length of post-operative inotropic support | Length of inotropic support used after admission to the ICU, if needed | First 30 days post-transplantation |
| Need for post-operative mechanical ventilation | Number of participants in need of mechanical ventilation upon admission to ICU | First 30 days post-transplantation |
| Length of post-operative mechanical ventilation | Length of intubation after admission to ICU, if mechanical ventilation needed | First 30 days post-transplantation |
| ICU length of stay | Length of stay in ICU post-transplant | First 30 days post-transplantation |
| Renal replacement therapy requirement | Number of participants who require renal replacement therapy during the first 10 days after liver transplantation, if not on renal replacement prior to transplant | First 30 days post-transplantation |
| Peak AST and ALT | Concentration of peak AST and ALT | First 7 days post-transplantation |
| Internal Normalized Ratio (INR) | INR measurements for each participant until post-op day 7 or discharge | First 7 days post-transplantation or within first 30 days post-op if discharge is longer than 7 days out |
| Total bilirubin | Total bilirubin measurement (mg/dl) on post-op day 7 or day of discharge | First 7 days post-transplantation or within first 30 days post-op if discharge is longer than 7 days out |
| 30-day patient survival | 30-day patient survival (percentage) | First 30 days post-transplantation |
| Re-listing for transplantation | Number of participants who require re-listing for liver transplantation within 30 days post-op | First 30 days post-transplantation |
| Adverse events | Incidence of any additional adverse events, not including 24-hour ICU stay post-transplant, post-transplant transfusion <=6 units pRBCs, <=2 units FFP, <=2 units 6-pack of platelets, as these are considered routine | First 30 days post-transplantation |
| Biopsy-proven rejection episodes | Number of participants with biopsy-proven rejection episodes | Assessed at 3, 6, and 12 months post-transplant |
| Liver function tests more than 3 times normal | Number of participants with liver function tests more than 3 times normal; liver function tests (LFTs) will measure AST/ALT, bilirubin, INR | Assessed at 3, 6, and 12 months post-transplant |
| Additional procedures | Number of participants that require additional procedures beyond normal recovery standard of care post-liver transplant | Assessed at 3, 6, and 12 months post-transplant |
| Re-admissions | Number of participants with re-admissions after initial discharge | Assessed at 3, 6, and 12 months post-transplant |
| Ischemic cholangiopathy and anastomotic strictures by imaging | Number of participants with evidence of ischemic cholangiopathy and anastomotic strictures by imaging | Assessed at 3, 6, and 12 months post-transplant |
| Vascular complications by cross-sectional imaging or angiography | Number of participants with evidence of vascular complications by cross-sectional imaging or angiography | Assessed at 3, 6, and 12 months post-transplant |
| Presence of steatosis by imaging or histology | Number of participants with evidence of steatosis by imaging or histology | Assessed at 3, 6, and 12 months post-transplant |
| Degree of steatosis by imaging or histology | Degree of steatosis by imaging or histology, if present | Assessed at 3, 6, and 12 months post-transplant |
| Renal dysfunction | Presence of a decrease in GFR > 40 from pre-transplant baseline or creatinine >2 if received simultaneous liver-kidney transplant | Assessed at 3, 6, and 12 months post-transplant |
| Hyperlipidemia | Number of participants with evidence of hyperlipidemia | Assessed at 3, 6, and 12 months post-transplant |
| Immunosuppression medications | Types of immunosuppression medications required | Assessed at 3, 6, and 12 months post-transplant |
| Dosage of immunosuppression medications | Dosage of immunosuppression medications required in respective unit measurement (i.e. milligrams) | Assessed at 3, 6, and 12 months post-transplant |
| Drug levels of immunosuppression medications | Drug levels of immunosuppression medications present in blood titers drawn from participant in respective unit measurement (i.e. ng/mL) | Assessed at 3, 6, and 12 months post-transplant |
| Re-listing for transplantation | Number of participants who require re-listing for transplantation within 1 year post-op | Assessed at 3, 6, and 12 months post-transplant |
| Graft failure | Number of participants with evidence of graft failure | Assessed at 3, 6, and 12 months post-transplant |
| Patient death | Number of participants with evidence of patient death | Assessed at 3, 6, and 12 months post-transplant |